Purchase Order HT001424P0003
Award Date 10/1/23
Potential Completion Date 10/10/23
Potential Value $116K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20889, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $139,428 firm fixed price purchase order to Biotheranostics Inc., a small disadvantaged business specializing in advanced molecular diagnostics and genomic testing services. The contract, which commenced on September 30, 2025 with an ultimate completion date of October 30, 2025, covers Breast Cancer Index (BCI) testing services to be performed at the Bethesda, Maryland location. This award represents a continuation of DHA's precision oncology efforts,...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Biotheranostics Inc., a self-certified small disadvantaged business, to provide Breast Cancer Index testing services for the Walter Reed National Military Medical Center. The $96,825 contract does not have a set-aside designation. Biotheranostics specializes in providing genomic diagnostic testing to support precision oncology and has been awarded multiple federal contracts by the Department of Veterans...
- The U.S. Defense Health Agency (DHA) has awarded a $139,428 firm fixed price purchase order to Biotheranostics Inc., a self-certified small disadvantaged business, to provide Breast Cancer Index testing services. This award, with a completion date of September 25, 2024, is not set aside and supports the DHA's efforts to enhance cancer care for veterans and service members through advanced molecular diagnostics that guide treatment planning. Biotheranostics, a division of Hologic, Inc., has...
- This $139,428.00 firm fixed price purchase order was awarded by the Defense Health Agency (DHA) to Biotheranostics Inc., a self-certified small disadvantaged business. The contract is for the provision of Biotheranostics' proprietary Breast Cancer Index genomic diagnostic testing services to support cancer care for the DHA's beneficiary population. This contract award represents one of several prime federal awards, totaling over $700,000 between 2021-2023, that Biotheranostics has received...
- Biotheranostics Inc., a small disadvantaged business and division of Hologic Inc., was awarded a $47.4K purchase order by Veterans Integrated Service Network 6 (VISN 6) for cancer identification testing services. The contract, issued on October 7, 2021, with an ultimate completion date of October 6, 2026, utilizes firm fixed-price pricing with no set-aside designation. Performance will occur in San Diego, California, where Biotheranostics maintains its headquarters and specializes in advanced...
- This federal contract award to Genomic Health, Inc. is for the provision of breast cancer testing services to the Defense Health Agency (DHA), a defense agency within the U.S. Department of Defense. The $125,000.00 Firm Fixed Price Blanket Purchase Agreement (BPA) contract does not utilize any set-aside designations and was awarded on September 21, 2016, with a completion date of September 20, 2017. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in genomic-based cancer...
- The Defense Health Agency awarded Genomic Health, Inc. a $145,066.32 firm fixed-price BPA call for Oncotype IQ genomic testing services, with an ultimate completion date of September 7, 2026. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in advanced genetic testing services focused on oncology diagnostics, particularly the Oncotype DX portfolio of gene expression assays. These tests support cancer screening, treatment selection, and disease monitoring across breast,...
- This is a firm fixed-price blanket purchase agreement (BPA) call awarded by the Defense Health Agency to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, to provide Oncotype DX breast cancer testing services. The contract has an ultimate completion date of February 8, 2018 and a ceiling value of $10,361.88. Genomic Health, Inc. is a for-profit organization that specializes in advanced genetic testing services for federal healthcare systems. The company has been awarded several...
- This award is for a purchase order of $78,364.30 to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, to provide breast cancer testing services to the Defense Health Agency. The contract has a firm fixed price pricing type and a completion date of September 30, 2016. Genomic Health is a for-profit organization that specializes in providing genomic cancer testing services to the federal government, including the Department of Veterans Affairs, Department of Defense, Air Force,...
- This federal contract award is for Oncotype DX breast cancer testing services provided by Genomic Health, Inc. to the Defense Health Agency. The $13,815.84 firm fixed-price contract is a Blanket Purchase Agreement (BPA) call, with a performance period ending on May 31, 2018. Genomic Health, a subsidiary of Exact Sciences Corporation, is a for-profit organization that specializes in providing advanced genetic testing services to federal healthcare systems. The company has several large Indefinite...